Erenumab (Aimovig® ) was the first monoclonal antibody approved for migraine prophylaxis in Germany in November 2018. This allowed for more than a year of practical experience with the use of this innovative substance in everyday clinical practice. In addition, the AMNOG procedure, including the two components of added benefit assessment and price negotiation, was completed (1), which should lead to greater transparency and safety in prescribing this still high-priced drug. Finally, the German Society for Neurology (DGN) and the German Migraine and Headache Society (DMKG) published an amendment to the guideline "Therapy of Migraine Attacks and Migraine Prophylaxis," which provides recommendations for migraine prophylaxis with monoclonal antibodies against CGRP or the CGRP receptor. This article is an update of the overview of the same name, “Migraine prophylaxis: Erenumab – Recommendations for practice”, published in May 2019 in the journal PAIN MEDICINE, which discusses and integrates the aforementioned new developments of the last year.

Download via the link below: 

Practical recommendations for erenumab – 2020 update